Published in AIDS Weekly, May 21st, 2001
"The low oral bioavailability of the HIV protease inhibitor (HPI) saquinavir is dramatically increased by co-administration of the HPI ritonavir," M.T. Huisman and colleagues explained in the journal Molecular Pharmacology. "P-gp is known to limit the ... brain, testis, and fetal penetration of its substrates, so effective inhibition of P-gp by ritonavir in vivo might open up pharmacological sanctuary sites" for the drugs.
However, Huisman and coworkers...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.